European PostASCO Meeting 2011

Dear colleagues and friends,

Metastatic melanoma is still considered as a disease that is extremely hard to treat. It shows a dismal prognosis and mainly effects middle-aged women and men. The current treatment options – apart from clinical trial participation – are very limited. New treatment modalities for this disease have not been approved for decades. However, we are expecting a significant improvement of the treatment options for melanoma in the near future. Numerous new therapies are emerging for the adjuvant treatment of high-risk melanoma patients, such as for non-resectable metastatic melanoma patients. New immunotherapeutic and targeted agents will be used either apart, or in combination. In addition to conventional chemotherapy, in-tralesional and loco-regional treatment methods are still of important value.

However, it will be the main target for all of us to choose the right patients for the right drugs! The aim of the Interdisciplinary Global Conference on Developing New Treatments for Melanoma in Munich is to grant a deep overall insight into the development of new drugs for melanoma. The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant.

International key opinion leaders will be invited to give an overview throughout specified presentations, to present latest clinical trial results, and to discuss on exciting new drugs with the audience at roundtables. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities of Germany.

Please join us for this melanoma event and submit your own studies and case presentations as free communications and as posters.

We look forward to welcoming you in Munich in July 2011!

Axel Hauschild, MD - Claus Garbe, MD, Conference Presidents